ReviewFrontiers in bioengineering and biotechnology2026
Characteristics of dermal fibroblasts and their biotherapeutic value in musculoskeletal system diseases.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the principal functional cells in the dermal layer of the skin, dermal fibroblasts can not only synthesize and remodel extracellular matrix components such as collagen and elastin, but also secrete a variety of growth factors and exert immunomodulatory functions. They play a pivotal role in maintaining skin structural homeostasis and wound repair, and their unique biological properties also make them a key subject of research in regenerative medicine. Musculoskeletal diseases (such as tendinopathy, fracture and intervertebral disc degeneration) are often accompanied by insufficient local tissue repair capacity, chronic inflammation and extracellular matrix degradation. In recent years, autologous or allogeneic fibroblast transplantation therapy has attracted increasing attention in orthopedic regenerative medicine. A number of clinical trials and basic studies have confirmed the beneficial effects of fibroblasts in promoting cartilage repair, alleviating inflammatory responses, improving tendon healing, and delaying intervertebral disc degeneration. This review systematically examines the sources, phenotypes, and functional characteristics of dermal fibroblasts. It focuses on their therapeutic potential in musculoskeletal system diseases (MSDs), including tendon injury, disc degeneration, and fracture healing. At the same time, it analyzes the challenges faced by current applications and the future directions for development, providing a theoretical reference for their clinical transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.